Rheumatoid synovial fluid cells and fibronectin purified human monocytes.
This Fluorescein (FITC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This Fluorescein conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
Blue Laser (488 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this 10.1 antibody for staining cells in flow cytometry is ≤ 5.0 μl per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone 10.1 recognizes the alpha subunit of human FCGR1.
FCGR1 is expressed on monocytes, macrophages, dendritic cells (DCs), and activated granulocytes.
FCGR1 antibody, 10.1, recognizes high-affinity immunoglobulin gamma Fc receptor I (FCGR1), also known as CD64. FCGR1 is a 72 kDa type I transmembrane glycoprotein expressed on monocytes, macrophages, and dendritic cells (DCs). FCGR1 can also be induced on neutrophils with IFNγ and G-CSF1. FCGR1 binds with high affinity to monomeric IgG1 and IgG3, and to a lesser extent, IgG42, resulting in phosphorylation of the intracellular FCGR1 ITAM motif and subsequent recruitment of Syk. FCGR1 contributes to inflammation via several mechanisms, including promoting antibody-dependent cell-mediated cytotoxicity (ADCC), clearance of immune complexes, cytokine production, and antigen presentation1,3. CD64-based targeted therapies eliminate M1 pro-inflammatory macrophages and show clinical potential for the treatment of macrophage-mediated chronic inflammatory diseases, such as chronic cutaneous inflammation and rheumatoid arthritis4. In addition, CD64 promotes antitumor responses and mediates cytotoxic killing of tumor cells by macrophages5.
References & Citations
1. Hulett MD & Hogarth PM. (1998) Mol Immunol. 35(14-15):989-96
2. M. Daëron., et al. (2009) Blood. 113: 3716–3725
3. Alter G., et al. (2011) Epub. 415(2):160-7
4. Barth S., et al. (2017) Biomedicines. 5(3):56
5. Keler T., et al. (1998) Clin Cancer Res. 4(9):2237-43
Products are for research use only. Not for use in diagnostic or therapeutic procedures.